Salmeterol

Generic Name: Salmeterol

Brand Names: Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 89365-50-4

Unique Ingredient Identifier: 2I4BC502BT

Background: Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.

Salmeterol was granted FDA approval on 4 February 1994.

Indication: 用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

Clinical Trials

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

Completed

Conditions: Obesity
Asthma

Interventions: Drug: Tiotropium bromide
Drug: Beclomethasone dipropionate HFA
Drug: Salmeterol xinafoate

First Posted Date: 2007-11-12

Last Posted Date: 2020-10-22

Lead Sponsor: National Jewish Health

Target Recruit Count: 33

Registration Number: NCT00557180

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 7 locations

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Salmeterol
Drug: Ciclesonide high
Drug: Fluticasone
Drug: Placebo
Drug: Ciclesonide low

First Posted Date: 2007-09-26

Last Posted Date: 2014-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT00535366

Locations: 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪
1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱
1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands

and more 9 locations

Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Placebo
Drug: Salmeterol

First Posted Date: 2007-09-18

Last Posted Date: 2012-05-23

Lead Sponsor: Novartis

Target Recruit Count: 27

Registration Number: NCT00531050

Locations: 🇧🇪
Novartis Investigative site, Antwerp, Belgium

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol 300 μg
Drug: Salmeterol 50 μg
Drug: Placebo to indacaterol
Drug: Placebo to salmeterol

First Posted Date: 2007-09-14

Last Posted Date: 2011-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 805

Registration Number: NCT00529529

Locations: 🇹🇷
Novartis Investigator Site, Izmir, Turkey
🇺🇸
Novartis Investigator Site x 2 sites, Pensacola, Florida, United States
🇺🇸
Novartis Investigator site, Houston, Texas, United States

and more 1 locations